Content :

Diabetes

February 05, 2013

Sanofi has an 85-year commitment to improving the health and wellbeing of diabetes patients.

 

Faced with the public health challenge of the worldwide diabetes epidemic, Sanofi aims to lead the fight against diabetes with a portfolio approach that includes Apidra® (insulin glulisine), Lantus® (insulin glargine) and Insuman® (human insulin).  Our current insulins are available in one or more of our most modern user friendly devices, ClikSTAR® and SoloSTAR®.

In 2012 Sanofi, together with its partner Agamatrix, launched a range of blood glucose monitors (BGM) including iBGStar® which is the first BGM to seamlessly connect to the Apple iPhone® and iPod Touch®.  For further information on the new BGStar® product range please visit Diabetes Matters, our website which helps to provide for the needs of everyone concerned about diabetes. 

 

In the UK, the number of people with diabetes is expected to increase to 4 million by 2025 and Sanofi also drives the agenda for more effective management of this condition through major awareness campaigns to highlight the importance of maintaining good glycaemic control and to encourage screening, good nutrition and physical exercise.  

Sanofi offers the information on this website for general educational and informational purposes only.  Product information is specific to the UK and is not intended to replace the advice of a healthcare professional. For information on Sanofi's product portfolio in the UK please visit the Our Products section of this website.